Breaking News

Opthea Licenses Selexis’ CHO-M Cell Line

By Kristin Brooks | January 14, 2014

To produce OPT-302 for Phase I trial in wet AMD

Opthea Pty Ltd. has entered into a commercial license agreement with Selexis SA to use its CHO-M Cell Line and related technologies for the production of OPT-302, an Fc fusion protein for the treatment of wet Age-Related Macular Degeneration (wet AMD). OPT-302 is scheduled to enter Phase I studies in early 2015 and is being developed by Opthea, a subsidiary of Circadian Technologies of Melbourne, Australia.
"Selexis is excited about the collaboration with Opthea and looks forward to seeing OPT-302 progress to clinical studies in wet AMD patients," said Dr. Igor Fisch, chief executive officer, Selexis SA. "The OPT-302 cell line demonstrates the power of our new technologies for the rapid generation of CHO cell lines expressing high yields of Fc fusion recombinant proteins. We look forward to continuing to work with Opthea."
"The productivity and speed of stable cell line generation with the SUREtechnology Platform is playing a key role in quickly progressing our candidate into clinical development," said Dr. Megan Baldwin, chief executive officer of Opthea. "By leveraging the SUREtechnology Platform, we were able to improve our titers by several fold."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research